A Pilot Study of the Effect of Sorafenib on Molecular Biomarkers in Barrett's Esophagus With High Grade Dysplasia
Phase of Trial: Phase II
Latest Information Update: 20 Oct 2013
At a glance
- Drugs Sorafenib (Primary)
- Indications Barrett's oesophagus; Oesophageal cancer
- Focus Biomarker; Pharmacodynamics
- 31 Aug 2018 Biomarkers information updated
- 20 Oct 2013 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
- 29 Feb 2008 New trial record.